Avexitide
- Generic Name
- Avexitide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C149H234N40O47S
- CAS Number
- 133514-43-9
- Unique Ingredient Identifier
- 5313W10MYT
- Background
Avexitide is under investigation in clinical trial NCT02996812 (Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia).
- Associated Conditions
- -
- Associated Therapies
- -
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer
Dan Monahan appointed Chief Commercial Officer at Amylyx, leading commercialization for avexitide, a GLP-1 receptor antagonist for post-bariatric hypoglycemia. With over 20 years of experience, Monahan aims to advance avexitide through Phase 3 trials, targeting unmet medical needs in PBH treatment.
Related Clinical Trials:
Amylyx announces design of LUCIDITY clinical trial
Amylyx announced the design of its Phase 3 LUCIDITY trial for avexitide, a GLP-1 receptor antagonist for post-bariatric hypoglycemia. The trial, expected to start in Q1 2025, will evaluate reduction in hypoglycemia events and safety, with topline data anticipated in 2026.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath